Targeted Nanoparticle Cancer Drug Strategy Attracts Funding
Developing a nanoparticle drug that promises to offer an alternative approach to chemotherapy with fewer side effects is a strategy that is attracting increasing interest in oncology circles. Among the many research groups worldwide involved in this field are Canadian researchers who have developed a drug-polymer conjugate that self-assembles into defined nanoparticles and, when injected, selectively accumulate in solid tumors. This promising research has attracted funding in order to set the technology along the road to eventual clinical trials.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter